Trial Profile

Phase 1 Trial of Safety and Preliminary Efficacy of Segmental Ablative Radioembolization in Combination with Tremelimumab Plus Durvalumab (MEDI4736) in Patients with Unresectable, or Oligo-Metastatic Cholangiocarcinoma Who Are Not Candidates for Curative Therapy (RAIDEN Trial)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Oct 2025 Planned number of patients changed from 18 to 16.
10 Oct 2025 Planned End Date changed from 30 Nov 2025 to 30 Nov 2028.
10 Oct 2025 Planned primary completion date changed from 30 Nov 2025 to 30 Nov 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com